The landscape of public health in India is marked by a high burden of vector-borne diseases (VBDs), which are a major cause of morbidity and mortality. This article aims to provide a comprehensive review of the prevalence and management of VBDs in India, focusing on diseases such as malaria, dengue, and chikungunya.
India carries a significant burden of VBDs. Malaria, for instance, is endemic in most of the country, with rural and tribal areas being the most affected. Dengue, on the other hand, has emerged as a major public health concern over the last few decades, with urban and semi-urban areas witnessing a surge in cases. Chikungunya, although less prevalent than malaria and dengue, has caused significant outbreaks in several states.
The management of VBDs in India involves a multipronged strategy that includes prevention, early detection, and treatment. Prevention strategies primarily involve vector control measures, such as the use of insecticide-treated nets and indoor residual spraying. Early diagnosis and prompt treatment are crucial for reducing morbidity and preventing complications. The National Vector Borne Disease Control Programme (NVBDCP) plays a pivotal role in the management of VBDs in India, providing guidelines and resources for prevention, diagnosis, and treatment.
The management of VBDs in India faces several challenges, including a lack of awareness, inadequate healthcare infrastructure, and resistance to insecticides. Future efforts should focus on strengthening disease surveillance, improving diagnostic facilities, and enhancing community participation in vector control activities. Research into new vector control methods and treatments is also crucial.
Understanding the prevalence and management of VBDs is critical for healthcare professionals in India. Despite the challenges, significant progress has been made in controlling these diseases. However, sustained efforts are required to further reduce the burden of VBDs and improve public health in India.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation